StockTitan

@stocktitan.net

2 days ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress Jaguar Health (NASDAQ:JAGX) family company Napo is a silver sponsor of the April 2-4, 2026 Elite Ped-GI Congress in Abu Dhabi and is supporting an investigator-initiated proof-of-concept study of crofelemer liquid in pediatric intestinal failure (IF) patients with MVID and SBS-IF.The study reported parenteral support (PS) reductions of 12–37% in ongoing patients treated >1 year; an abstract on long-term safety and efficacy was submitted for ESPGHAN June 2026. The global SBS/IF market is estimated at $8.0 billion by 2033.

#JAGX Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

2 weeks ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) Jaguar Health (NASDAQ:JAGX) said FDA feedback supports a protocol amendment to permit a single-blind extension of Napo's crofelemer trial in pediatric microvillus inclusion disease (MVID). The extension aims to assess longer-term clinical benefit by reducing parenteral support (PS), with dose selection by an independent DMC.Approximately 30% of patients have completed the double-blind phase; sites include the US, Italy and UAE. Company highlighted potential for a Breakthrough Therapy designation to enable expedited pathways.

#JAGX FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

www.stocktitan.net/news/JAGX/fda-feedback-s...

StockTitan

@stocktitan.net

3 weeks ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts Jaguar Health (NASDAQ:JAGX) announced that CEO Lisa Conte will present virtually at the Life Sciences Virtual Investor Forum on Thursday, March 12, 2026 at 2:00 PM Eastern. Registration is available through the conference site and a replay of the webcast will be posted after the event.

#JAGX Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

3 weeks ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants Jaguar Health (NASDAQ:JAGX) said it strengthened its balance sheet by restructuring royalty and debt obligations with affiliates of Chicago Venture Partners L.P., including extinguishing 48,212 warrants.The deal cut royalty/debt by ~10% (~$3 million), extended a secured revolving credit maturity by three years for ~$7 million, and left no affiliate-held debt maturing before July 2026. The company said it will pursue additional restructuring and continues development of its crofelemer powder-for-oral-solution program for rare-disease intestinal failure.

#JAGX Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

1 month ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 Jaguar Health (NASDAQ:JAGX) received a $3.0 million payment from Future Pak after Jaguar terminated the buy-back provision in its January 2026 U.S. licensing agreement for Mytesi and Canalevia-CA1. Jaguar earlier received $16.0 million of non-dilutive capital, with $2.0 million contingent and up to $20.0 million in future milestones.Jaguar will continue manufacturing both crofelemer products while Future Pak holds U.S. marketing rights; Jaguar targets an NDA filing for MVID in H1 2027 and is pursuing Breakthrough Therapy designation.

#JAGX Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

www.stocktitan.net/news/JAGX/jaguar-health-...

tickerade

@tickerade.bsky.social

2 months ago

#JAGX on the move as Jaguar Health re-enters position

StockTitan

@stocktitan.net

2 months ago

Healthcare summit talk: Jaguar Health's Jan. 15 virtual investor update Hear Jaguar Health's CEO speak at 3:30 PM ET Jan. 15 during the Lytham Partners Healthcare Investor Summit, with a replay available online.

#JAGX Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

2 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million Jaguar Health (NASDAQ: JAGX) entered a U.S. license agreement with Future Pak on January 12, 2026, granting Future Pak exclusive U.S. marketing rights for Mytesi (crofelemer) and Canalevia-CA1 while Jaguar will remain the manufacturer.Jaguar will receive an $18 million upfront payment ($16M at closing, $2M on post-closing conditions) and is eligible for up to $20 million in milestone and other future payments. The agreement includes a 12-month Jaguar right to reacquire rights for mutually agreed additional crofelemer indications upon U.S. regulatory approval. Jaguar said the deal provides non-dilutive capital to focus crofelemer development on rare-disease indications, with Phase 2 study results for MVID expected in March 2026.

#JAGX Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

2 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failureAssociated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can

#JAGX Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

www.stocktitan.net/news/JAGX/article-about-...

StockTitan

@stocktitan.net

3 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000

#JAGX Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

3 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs Jaguar Health (NASDAQ:JAGX) announced the FDA renewed the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs, effective through December 21, 2026. The company said this renewal represents the fifth and final allowable year of conditional approval.A confirmatory effectiveness trial is underway and is expected to conclude in February 2026, ahead of the FDA's June deadline; the study has enrolled 51 dogs to date with approximately 49 more expected. Canalevia-CA1 is available from multiple leading U.S. veterinary distributors, including Chewy.

#JAGX FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

www.stocktitan.net/news/JAGX/fda-approves-r...

StockTitan

@stocktitan.net

3 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all three proposals at the Special Meeting held on December 8, 2025. The company highlighted early clinical and regulatory developments for crofelemer in microvillus inclusion disease (MVID): an investigator-initiated proof-of-concept trial showed crofelemer may extend infant lives and reduce total parenteral support (PS) volumes by up to 37%, though the report notes associated toxicity. Jaguar completed a meeting with the FDA on October 2, 2025 to seek advice on advancing its placebo-controlled crofelemer trial toward a possible expedited approval pathway. CEO Lisa Conte will present updates on December 10, 2025, 3:25–3:35 PM ET at the Emerging Growth Conference.

#JAGX Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

www.stocktitan.net/news/JAGX/jaguar-health-...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Small-cap stocks with strong volume declines, Tue Dec 2nd - #BGLC #CDLR #ABTC #EPOW #BLTE #HKIT #DBVT #NIVF #DOGZ #RYOJ #FTEL #SDH #GIBO #WOK #JAGX #SONN #YKDG - More: crystalequityresearch.com/leading-indi... - #smallcap

StockTitan

@stocktitan.net

4 months ago

#JAGX Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

www.stocktitan.net/news/JAGX/jaguar-health-...

PRISM MarketView

@prismmarketview.bsky.social

4 months ago

PRISM M☀️RNING M☀️VERS
In the Green - Premarket Gainers
( #MIGI) - up 10% at $5.65
( #MTEN) - up 9% at $1.88
( #BRN) - up 9% at $1.20
( #AMTM) - up 8% at $27.57

In the Red - Premarket Losers
( #FOXX) - down 13% at $4.00
( #JAGX) - down 11% at $1.13

StockTitan

@stocktitan.net

4 months ago

#JAGX Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

4 months ago

#JAGX Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

4 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates Jaguar Health (NASDAQ:JAGX) announced it will file its Form 10-Q for the quarter ended September 30, 2025 on November 14, 2025 and will host an investor webcast to review Q3 2025 financials and corporate updates.The webcast is scheduled for Monday, November 17, 2025 at 8:30 AM Eastern. Registration and participant access are available via the company’s registration link.

#JAGX Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

6 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs Jaguar Health (NASDAQ:JAGX) has received notice of a $250,000 FDA grant to fund a confirmatory trial for Canalevia-CA1, their conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs. The grant would support studies required for full FDA approval, though the company has not yet accepted the award.The company is in discussions with multiple animal health partners to expand Canalevia's indication to treat general diarrhea in dogs, targeting both U.S. and European markets. The potential market is substantial, with an estimated 11 million dogs suffering from general diarrhea annually in the U.S. and approximately 104 million dogs in Europe.Canalevia contains crofelemer, a plant-based prescription drug that reduces diarrhea without using antibiotics. The drug is currently available through major U.S. veterinary distributors for CID treatment in dogs.

#JAGX Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

6 months ago

Biotech Leader Jaguar Health Sets Dual Conference Appearances: Key Updates Coming at September Events Jaguar Health's CEO Lisa Conte to present virtually at Emerging Growth Conference on Sept 25 and Lytham Partners Fall Conference on Sept 30, providing updates on near-term catalysts.

#JAGX Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

6 months ago

Biotech CEO Lisa Conte of Jaguar Health to Present Company Updates at Major H.C. Wainwright Conference Jaguar Health's CEO Lisa Conte will deliver virtual presentation at H.C. Wainwright Global Investment Conference on Sept 8-10, 2025. Available on-demand from Sept 5.

#JAGX Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

7 months ago

27% TPN Reduction: Jaguar Health's Crofelemer Shows Promise in MVID Trial Ahead of FDA Strategy Jaguar Health secures stockholder approval for 7 proposals at annual meeting. Crofelemer shows 27% TPN reduction in MVID trial, 12.5% in SBS-IF. Company pursuing partnerships for orphan drugs.

#JAGX Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

7 months ago

Jaguar Health's Q2 Revenue Surges 35% as Rare Disease Drug Shows Promise in Clinical Trials Jaguar Health achieves $3M Q2 revenue while its drug reduces parenteral nutrition needs by up to 27% in rare disease patients. Company seeks strategic partnerships for orphan drugs. Learn more.

#JAGX Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

7 months ago

Jaguar Health Announces Double Header: Q2 Earnings Call and Emerging Growth Conference Presentation This Week Join Jaguar Health's Q2 earnings webcast and get exclusive corporate updates. Plus, catch CEO Lisa Conte at the Emerging Growth Conference. Register now.

#JAGX Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

8 months ago

Clinical Trial Launches for First FDA-Approved Dog Diarrhea Treatment, Targeting $6B Pet Health Market First FDA-approved treatment for chemotherapy-induced diarrhea in dogs enters clinical trial phase. Expansion planned for 104M EU pet market. See enrollment data.

#JAGX Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

www.stocktitan.net/news/JAGX/enrollment-ini...

StockTitan

@stocktitan.net

9 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient Jaguar Health (NASDAQ:JAGX) announced positive proof-of-concept results for their drug crofelemer in treating a third intestinal failure patient. The novel liquid formulation demonstrated efficacy in reducing total parenteral nutrition (TPN) requirements in a second pediatric patient with short bowel syndrome (SBS-IF).The results build on previously reported data showing crofelemer reduced TPN requirements by up to 27% in microvillus inclusion disease (MVID) patients and up to 12.5% in SBS-IF patients. Notably, when the first two patients were taken off crofelemer after 12 weeks of treatment, their symptoms worsened, leading to prompt reinstatement of the treatment.The company is conducting multiple studies, including two independent proof-of-concept investigator-initiated trials (IITs) and two placebo-controlled Phase 2 studies. The Phase 2 study in pediatric MVID patients is expected to complete by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize their intestinal failure products, aiming to generate non-dilutive funding. [ "Crofelemer reduced TPN requirements by up to 27% in MVID patients and 12.5% in SBS-IF patients", "Second pediatric SBS-IF patient showed similar positive response for TPN reduction", "No safety issues reported at highest protocol-approved dose", "Results may support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program", "Data could support reimbursed early patient access in EU countries" ]

#JAGX Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

www.stocktitan.net/news/JAGX/proof-of-conce...

StockTitan

@stocktitan.net

9 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs Jaguar Health (NASDAQ:JAGX) announced plans to pursue European Medicines Agency approval for Canalevia to treat general diarrhea in dogs in the EU. The drug, which contains plant-based crofelemer, is currently conditionally FDA-approved for chemotherapy-induced diarrhea in dogs under the name Canalevia-CA1.The company is in discussions with potential animal health partners to achieve three goals: EU approval for general diarrhea treatment, maintaining U.S. availability for chemotherapy-induced diarrhea, and expanding U.S. indication to include general diarrhea. A completed study of 200 dogs showed significant improvement in fecal scores using a revised endpoint analysis. The potential market is substantial, with 104 million dogs in Europe and approximately 6 million annual cases of acute and chronic diarrhea in U.S. veterinary practices.

#JAGX Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

9 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 Jaguar Health (NASDAQ:JAGX) has announced the extension of maturity date for its convertible promissory notes from June 30, 2025 to January 30, 2026. The extension applies to approximately $2.57 million in aggregate principal amount from the original $3.448 million bridge financing that closed on March 31, 2025. Prior to this extension, five investors converted $0.866 million (including accrued interest) into company equity.The bridge financing participants include the company's CEO, board members, other C-suite executives, and institutional and accredited investors. The funding aims to support Jaguar's three core development programs for crofelemer: orphan disease intestinal failure program, cancer therapy-related diarrhea treatment, and expansion of Canalevia® for dogs.

#JAGX Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

9 months ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer Jaguar Health (NASDAQ:JAGX) reports progress in its orphan disease intestinal failure program for crofelemer. The Phase 2 study for microvillus inclusion disease (MVID) in pediatric patients has reached 25% enrollment, while the SBS-IF study in adults is above 10%. Initial proof-of-concept results show crofelemer reduced total parenteral nutrition requirements by up to 27% in MVID patients and 12.5% in short bowel syndrome patients. The company expects to complete its randomized Phase 2 MVID study by mid-2026. Jaguar is actively seeking business development partnerships for licensing rights to develop and commercialize its intestinal failure products, aiming to generate non-dilutive funding. The positive early results could potentially support inclusion in EMA's PRIME program and FDA's Breakthrough Therapy program, potentially accelerating regulatory approval pathways.

#JAGX Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

www.stocktitan.net/news/JAGX/jaguar-health-...

StockTitan

@stocktitan.net

9 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts Jaguar Health (NASDAQ:JAGX) announced that its founder, president and CEO Lisa Conte will deliver a virtual presentation at the Emerging Growth Conference on June 18, 2025, from 9:40 - 10:10 AM Eastern Time. The presentation will be available online, with a replay accessible through EmergingGrowth.com and the Emerging Growth YouTube Channel. This conference presentation aims to provide updates on near-term catalysts for the company.

#JAGX Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

www.stocktitan.net/news/JAGX/jaguar-health-...